Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

126 to 150 of 261 results

Expanded indication for Janssen's Zytiga cleared in EU

14-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International said Friday…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationZytiga

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11-01-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen

07-01-2013

Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Janssen's TB drug Sirturo gains US FDA approval

02-01-2013

The US Food and Drug Administration has granted accelerated approval for US health care major Johnson…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSirturo

Public Citizen urges FDA to reject accelerated approval for Janssen's bedaquiline

27-12-2012

The US Food and Drug Administration should not approve the anti-tuberculosis drug bedaquiline from Janssen,…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonNorth AmericaPharmaceuticalRegulation

Evotec in up to $175 million NMDA antagonist license deal with Janssen

19-12-2012

Germany's Evotec (EVT: TecDAX) has entered into a license agreement with Janssen Pharmaceuticals, a subsidiary…

EvotecJanssenJohnson & JohnsonLicensingNeurologicalPharmaceutical

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Janssen files Stelara for active psoriatic arthritis in USA and EU

07-12-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen yesterday submitted a supplemental…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationStelara Injection

Zeltia's Yondelis approved for sale in 10 new countries

04-12-2012

Pharma Mar, a subsidiary of Spain's Grupo Zeltia (ZEL: MC), says it has been advised by its licensee…

GlobalJanssenJohnson & JohnsonOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

Johnson & Johnson CEO Alex Gorsky to also takeover role of chairman

02-12-2012

US health care giant Johnson & Johnson (NYSE: JNJ) has elected Alex Gorsky to assume the chairman title…

Johnson & JohnsonManagementPharmaceutical

Big Pharma doing more for access to medicine in developing countries than two years ago

28-11-2012

The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts…

AstraZenecaBayerGlaxoSmithKlineGlobalHealthcareJohnson & JohnsonMerck KGaAPharmaceuticalPricingResearch

FDA staffers seem to back safety of Janssen bedaquiline (Sirturo)

27-11-2012

Ahead of the November 28 meeting of the US Food and Drug Administration's Anti-Infective Drugs Advisory…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySirturo

Highlights of ACR meeting include new Cimzia, Stelara and Simponi data

13-11-2012

Belgian drugmaker UCB (UCB: BR) presented results for Cimzia (certolizumab pegol), from the Phase III…

Anti-Arthritics/RheumaticsCimziaJohnson & JohnsonPharmaceuticalResearchSimponi InjectionStelara InjectionUCB

Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021

13-11-2012

The atrial fibrillation drug market will experience dramatic growth over the next decade, increasing…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Incivo plus peginterferon and ribavirin positive for co-infected hep C and HIV patients, says Janssen

12-11-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Infectious Diseases - Diagnostics BVBA presented…

Anti-viralsBiotechnologyIncivoJanssenJohnson & JohnsonPharmaceuticalResearch

126 to 150 of 261 results

Parexel

Parexel

Back to top